#ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months

June 8, 2026 04:15 PM EDT R&DPharmaGLP-1 drugs As­traZeneca's obe­si­ty pill match­es ri­vals in Phase 2, an­chor­ing $5B fran­chise push Elizabeth Cairns Senior biopharma journalist The race to be third to mar­ket with an obe­si­ty pill has a num­ber of con­tenders, in­clud­ing Roche, Pfiz­er and Struc­ture Ther­a­peu­tics. On Mon­day, As­traZeneca … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER